Table 2.
Adverse events (AE) of grade ≥3 (n = 29 patients).
| System Organ Class, Preferred Term | N (%) |
|---|---|
| Patients with any AE of grade ≥ 3 | 19 (66) |
| Blood and lymphatic system disorders | |
| Neutropenia | 3 (10) |
| Lymphopenia | 1 (3) |
| Investigations | |
| Blood alkaline phosphatase increased | 4 (14) |
| Aspartate aminotransferase increased | 3 (10) |
| Alanine aminotransferase increased | 2 (7) |
| Cortisol decreased | 1 (3) |
| Skin and subcutaneous tissue disorders | |
| Rash | 2 (7) |
| Gastrointestinal disorders | |
| Colitis | 1 (3) |
| Nausea | 1 (3) |
| Stomatitis | 1 (3) |
| Metabolism and nutrition disorders | |
| Hyperglycemia | 1 (3) |
| Hypokalemia | |
| Hyponatremia | 1 (3) |
| Endocrine disorders | 1 (3) |
| Hypophysitis | 1 (3) |
| Respiratory, thoracic and mediastinal disorders | |
| Pulmonary embolism | 1 (3) |
| Musculoskeletal and connective tissue disorders | |
| Back pain | 1 (3) |
| Lupus-like syndrome | 1 (3) |
| Hepatobiliary disorders | |
| Jaundice | 1 (3) |
| Nervous system disorders | |
| Insomnia | 1 (3) |
| General disorders and administration site conditions | |
| Chest pain | 1 (3) |